ArticleWomen's health reports (New Rochelle, N.Y.)2025
Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy-A Post Hoc Analysis of the CopenFast Trial.
Article in Women's health reports (New Rochelle, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To explore sensor-derived glycemic metrics during pregnancy in women with type 1 diabetes using insulin degludec or other basal insulin analogs. Methods: A post hoc analysis of 87 pregnant women with type 1 diabetes using intermittently scanned continuous glucose monitoring and multiple daily injections, including basal insulin analogs in the CopenFast trial. Glycemic metrics, including mean sensor glucose, time in range (TIRp, 3.5-7.8 mmol/L), and time below range in pregnancy (TBRp, <3.5 mmol/L), were assessed from periconception to 37 completed weeks. Results: In total, 58 women used degludec and 29 women used other basal insulin analogs. At baseline (median = 9.5 gestational weeks, interquartile range = 9.0-11.0), hemoglobin A1c was 50 ± 9 versus 46 ± 6 ( Conclusions: In this post hoc analysis, pregnant women with type 1 diabetes using degludec achieved lower nighttime TIRp, experienced less severe hypoglycemia, and delivered infants who were heavier and thereby had less appropriate size compared with women using other basal insulin analogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.